Disease | N. SNPs d | DSI v | DPI v | Chr | Position | Consequence | Alleles | Class | AFEXOME | AFGENOME | Score vda | EI vda | N. PMIDs | First Ref. | Last Ref. | ||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Neoplasms
|
1571 | 0.526 | 0.560 | 3 | 179234297 | missense variant | A/G;T | snv | 4.0E-06; 4.0E-06 | 0.800 | 0.909 | 21 | 2006 | 2019 | |||||
Malignant neoplasm of breast
|
2154 | 0.526 | 0.560 | 3 | 179234297 | missense variant | A/G;T | snv | 4.0E-06; 4.0E-06 | 0.800 | 1.000 | 19 | 2006 | 2019 | |||||
Breast Carcinoma
|
2145 | 0.526 | 0.560 | 3 | 179234297 | missense variant | A/G;T | snv | 4.0E-06; 4.0E-06 | 0.100 | 1.000 | 16 | 2006 | 2019 | |||||
Malignant Neoplasms
|
1441 | 0.526 | 0.560 | 3 | 179234297 | missense variant | A/G;T | snv | 4.0E-06; 4.0E-06 | 0.090 | 1.000 | 9 | 2012 | 2018 | |||||
Primary malignant neoplasm
|
1374 | 0.526 | 0.560 | 3 | 179234297 | missense variant | A/G;T | snv | 4.0E-06; 4.0E-06 | 0.080 | 1.000 | 8 | 2012 | 2018 | |||||
Carcinogenesis
|
355 | 0.526 | 0.560 | 3 | 179234297 | missense variant | A/G;T | snv | 4.0E-06; 4.0E-06 | 0.060 | 0.833 | 6 | 2012 | 2019 | |||||
Mammary Neoplasms
|
78 | 0.526 | 0.560 | 3 | 179234297 | missense variant | A/G;T | snv | 4.0E-06; 4.0E-06 | 0.740 | 1.000 | 4 | 2004 | 2016 | |||||
Liver carcinoma
|
769 | 0.526 | 0.560 | 3 | 179234297 | missense variant | A/G;T | snv | 4.0E-06; 4.0E-06 | 0.730 | 1.000 | 3 | 2008 | 2019 | |||||
Neoplasm Metastasis
|
327 | 0.526 | 0.560 | 3 | 179234297 | missense variant | A/G;T | snv | 4.0E-06; 4.0E-06 | 0.030 | 0.667 | 3 | 2013 | 2019 | |||||
Carcinoma
|
90 | 0.526 | 0.560 | 3 | 179234297 | missense variant | A/G;T | snv | 4.0E-06; 4.0E-06 | 0.020 | 1.000 | 2 | 2011 | 2018 | |||||
Colorectal Carcinoma
|
1186 | 0.526 | 0.560 | 3 | 179234297 | missense variant | A/G;T | snv | 4.0E-06; 4.0E-06 | 0.820 | 1.000 | 2 | 2005 | 2016 | |||||
Hidradenoma Papilliferum
|
5 | 0.526 | 0.560 | 3 | 179234297 | missense variant | A/G;T | snv | 4.0E-06; 4.0E-06 | 0.020 | 1.000 | 2 | 2016 | 2017 | |||||
Malignant neoplasm of colon and/or rectum
|
502 | 0.526 | 0.560 | 3 | 179234297 | missense variant | A/G;T | snv | 4.0E-06; 4.0E-06 | 0.020 | 1.000 | 2 | 2013 | 2016 | |||||
Mammary Tumorigenesis
|
5 | 0.526 | 0.560 | 3 | 179234297 | missense variant | A/G;T | snv | 4.0E-06; 4.0E-06 | 0.020 | 1.000 | 2 | 2013 | 2016 | |||||
Adenocarcinoma of lung (disorder)
|
183 | 0.526 | 0.560 | 3 | 179234297 | missense variant | A/G;T | snv | 4.0E-06; 4.0E-06 | 0.710 | 1.000 | 1 | 2016 | 2017 | |||||
Adenoma
|
103 | 0.526 | 0.560 | 3 | 179234297 | missense variant | A/G;T | snv | 4.0E-06; 4.0E-06 | 0.010 | 1.000 | 1 | 2017 | 2017 | |||||
Anaplasia
|
7 | 0.526 | 0.560 | 3 | 179234297 | missense variant | A/G;T | snv | 4.0E-06; 4.0E-06 | 0.010 | 1.000 | 1 | 2015 | 2015 | |||||
Anaplastic thyroid carcinoma
|
16 | 0.526 | 0.560 | 3 | 179234297 | missense variant | A/G;T | snv | 4.0E-06; 4.0E-06 | 0.010 | 1.000 | 1 | 2014 | 2014 | |||||
Apocrine metaplasia
|
1 | 0.526 | 0.560 | 3 | 179234297 | missense variant | A/G;T | snv | 4.0E-06; 4.0E-06 | 0.010 | 1.000 | 1 | 2013 | 2013 | |||||
Biliary Tract Cancer
|
11 | 0.526 | 0.560 | 3 | 179234297 | missense variant | A/G;T | snv | 4.0E-06; 4.0E-06 | 0.010 | 1.000 | 1 | 2015 | 2015 | |||||
Bladder Neoplasm
|
278 | 0.526 | 0.560 | 3 | 179234297 | missense variant | A/G;T | snv | 4.0E-06; 4.0E-06 | 0.010 | 1.000 | 1 | 2017 | 2017 | |||||
Carcinoma breast stage IV
|
14 | 0.526 | 0.560 | 3 | 179234297 | missense variant | A/G;T | snv | 4.0E-06; 4.0E-06 | 0.010 | 1.000 | 1 | 2019 | 2019 | |||||
Carcinoma of bladder
|
290 | 0.526 | 0.560 | 3 | 179234297 | missense variant | A/G;T | snv | 4.0E-06; 4.0E-06 | 0.010 | 1.000 | 1 | 2017 | 2017 | |||||
Carcinoma of lung
|
995 | 0.526 | 0.560 | 3 | 179234297 | missense variant | A/G;T | snv | 4.0E-06; 4.0E-06 | 0.010 | 1.000 | 1 | 2015 | 2015 | |||||
Carcinoma, Ovarian Epithelial
|
321 | 0.526 | 0.560 | 3 | 179234297 | missense variant | A/G;T | snv | 4.0E-06; 4.0E-06 | 0.010 | 1.000 | 1 | 2016 | 2016 |